![]() |
![]() |
![]() |
![]() |
PO-001 | NGS cannot replace standard Fragment Analysis for the Detection of FLT3-ITD | Amanda Gilkes | ![]() |
![]() |
|||
PO-002 | Shedding smart light on the effectiveness of chemotherapy; using Raman spectroscopy and machine learning to differentiate the effects of cytarabine toxicity and crosstalk of leukaemic and bone marrow stromal cells. | Jen May | ![]() |
![]() |
|||
PO-003 | EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS | Ciro Rinaldi | ![]() |
![]() |
|||
PO-004 | HIV status does not impact on the outcome of patients with Burkitt lymphoma: a UK analysis | Xiao-Yin Zhang | ![]() |
![]() |
|||
PO-005 | Efficacy and Safety of Mogamulizumab by Patient Blood Classification | Lay Ean Tan | ![]() |
![]() |
|||
PO-006 | Isolated drenching night sweats a critical review of 2 Week Wait primary care referral to Birmingham haematology clinicsBirmingham Heartlands, Good Hope and Solihull Hospitals, University Hospitals Birmingham | Clare Gardner | ![]() |
![]() |
|||
PO-007 | Clinical characteristics and molecular insights into pathogenesis of peripheral T-cell lymphoma: A SEER population-based study of 11,463 patients and biological analysis | Qiaoli Li | ![]() |
![]() |
|||
PO-008 | Acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukaemia: A meta-analysis of randomised controlled trials | Thura Htut | ![]() |
![]() |
|||
PO-009 | Mechanisms of acquired resistance in B cell malignancies treated with the ive BTK inhibitor (BTKi), tirabrutinib | Ross Jackson | ![]() |
![]() |
|||
PO-010 | Impact of COVID-19 on peripheral blood stem cell mobilisation for myeloma patients A single centre experience at University College London Hospitals | Marquita Camilleri | ![]() |
![]() |
|||
PO-011 | Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma | Alex Medaglia | ![]() |
![]() |
|||
PO-012 | Adrenal Insufficiency Following Prolonged Exogenous Steroid Treatment for Graft Versus Host Disease | Ann Tivey | ![]() |
![]() |
|||
PO-013 | Impact of SARS-CoV-2 (COVID 19 infection) & MDS in the UK: results of a patient survey to document shielding uptake and patient experience following changes to consultation practice. | Pramila Krishnamurthy | ![]() |
![]() |
|||
PO-014 | Avapritinib Induces Responses in Patients with Advanced Systemic Mastocytosis, Regardless of Prior Midostaurin Therapy | Deepti Radia | ![]() |
![]() |
|||
PO-015 | CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY | Mark Drummond | ![]() |
![]() |
|||
PO-016 | Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients is infrequent and does not lead to increased mortality | Andrew Duncombe | ![]() |
![]() |
|||
PO-017 | A Machine Learning Approach to Predicting MPN Patients | Graeme Greenfield | ![]() |
![]() |
|||
PO-018 | ITP and its management in the UK during the COVID-19 pandemic: interim results of a national audit. | Edmund Watson | ![]() |
![]() |
|||
PO-019 | Fostamatinib Treatment of Warm Antibody Autoimmune Hemolytic Anemia: A Global, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study | Duncan Stacey | ![]() |
![]() |
|||
PO-020 | Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria | Morag Griffin | ![]() |
![]() |
|||
PO-021 | Assessment of the Longitudinal Effects of Luspatercept on Iron Overload and Iron Chelation Therapy Usage in Adults With -thalassaemia Enrolled in the Phase 3 BELIEVE Study | Karolina Lech | ![]() |
![]() |
|||
PO-022 | A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis | Sheema Sheikh | ![]() |
![]() |
|||
PO-023 | Haematological Indices and Haemoglobin High Pressure Liquid Chromatography for diagnosis of Haemoglobinopathies in a Secondary care centre in North East India | Mahendra Mishra | ![]() |
![]() |
|||
PO-024 | Eligibility for emerging therapies in sickle cell disease | Sona Vora | ![]() |
![]() |
|||
PO-025 | COVID-19 VTE Champions: a supportive quality improvement programme that optimised thromboprophylaxis in patients with COVID-19 | Rebecca Price | ![]() |
![]() |
|||
PO-026 | The development of an ambulatory community service for post HSCT patients to promote shielding during the SARS-CoV-2 pandemic | Rebecca Hallam | ![]() |
![]() |
|||
PO-027 | Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19. | Jen May | ![]() |
![]() |
|||
PO-028 | One Step At A Time: Delivering A Safe Laboratory Service For Transfusion | Victoria Tuckley | ![]() |
![]() |
|||
PO-029 | Joint Health Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) in a Real-world Setting: Results of a 6-year Interim Analysis of the AHEAD International Study | Kate Khair | ![]() |
![]() |
|||
PO-030 | DOES APIXABAN PRETREATMENT ALTER ALTEPLASE-INDUCED THROMBOLYSIS: AN IN VITRO STUDY? | Sandra Thalerová | ![]() |
![]() |
|||
PO-031 | Point of Care Testing to monitor Vitamin K Antagonist International Normalised Ratio (INR) control in patients with Antiphospholipid Syndrome during the COVID-19 pandemic | Michael Masucci | ![]() |
![]() |
|||
PO-032 | Quality of life and its predictors among adult patients with haemophilic arthropathy | Roberto Ucero-Lozano | ![]() |
![]() |
|||
PO-033 | Anthracycline-induced cardiomyopathy in paediatric acute myeloid leukaemia-A single centre age-stratified retrospective analysis and the early impact of dexrazoxane | Claire Horgan | ![]() |
![]() |
|||
PO-034 | A regional experience of NGS Myeloid panels in Myeloid Haematological malignancies | Ferkhanda Zareen | ![]() |
![]() |
|||
PO-035 | Response of Immunosuppressive Therapy in patients of Acquired Aplastic Anaemia: Real world experience from a developing country | Sobia Umar | ![]() |
![]() |
|||
PO-036 | Prognostic significance of BAALC expression in cytogenetically normal acute myeloid leukemia | Anita Chopra | ![]() |
![]() |
|||
PO-037 | The Molecular Landscape of Acute Myeloid Leukaemia in Northern Ireland | Graeme Greenfield | ![]() |
![]() |
|||
PO-038 | Cytogenetic and mutational profile analysis of CD56-positive Acute Myeloid Leukaemia: A single centre experience | Vita Ceidiene | ![]() |
![]() |
|||
PO-039 | Use of Non-funded Drugs in advanced haematological malignancies | Asma Batool | ![]() |
![]() |
|||
PO-040 | CARBOHYDRATE COMPONENTS OF GLYCOCONJUGATES OF BLAST CELL MEMBRANES IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS | Olha Shalay | ![]() |
![]() |
|||
PO-041 | An audit of fever-2-needle time in haemato-oncology patients during COVID-19. | Sasha-Nicole Temple | ![]() |
![]() |
|||
PO-042 | Ensembl variant effect predictor results and other phenotypes reported on the clinically pathogenic variants identified on patients with CD56-positive Acute Myeloid Leukaemia | Mahesh Prahladan | ![]() |
![]() |
|||
PO-043 | Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients with Acute Myeloid Leukemia: A Single Center Experience | Tarinee Rungjirajitranon | ![]() |
![]() |
|||
PO-044 | Myeloid sarcoma: a single centre experience | Christopher Mullen | ![]() |
![]() |
|||
PO-045 | Spontaneous regression of acute myeloid leukemia following SARS-CoV-2 infection | Kinda Al-Hourani | ![]() |
![]() |
|||
PO-046 | All-trans retinoic acid induced myocarditis as a feature of differentiation syndrome: a case report and literature review | Na Hyun Kim | ![]() |
![]() |
|||
PO-047 | FLT3-ITD negative relapse following FLT3 inhibition | Christopher Mullen | ![]() |
![]() |
|||
PO-048 | A case of thrombotic stroke in a newly diagnosed APML. | Mohammed Hatata | ![]() |
![]() |
|||
PO-049 | Diagnostic yield and safety of splenic core biopsy A single Centre experience | Francis Anyanwu | ![]() |
![]() |
|||
PO-050 | Patient feedback on Lymphoma services during the COVID pandemic | charlotte bloodworth | ![]() |
![]() |
|||
PO-051 | A Clinical Audit of Discharge Plans for Haemato-oncology Inpatients at Queen Elizabeth Hospital, Birmingham; Implementing the Safe Discharge Guideline. | Iman Qureshi | ![]() |
![]() |
|||
PO-052 | Impact of the Covid-19 Pandemic on Haematology Research Trials at The Christie Hospital | Sana Saleem | ![]() |
![]() |
|||
PO-053 | The On-Control Powered Bone Marrow Device: an Audit of 100 Patients in Oxford | Faye Sharpley | ![]() |
![]() |
|||
PO-054 | Should we replace telephone with video consultation to improve patient experience? - The Queen Elizabeth Hospital experience | Matthew Horan | ![]() |
![]() |
|||
PO-055 | The Impact of the COVID19 Pandemic on the Diagnosis of Myeloid Malignancies: a Single Institution Experience. | Razan Elbashir | ![]() |
![]() |
|||
PO-056 | Assisting Trainees with Differential Leucocyte Count Experiment using Deep Learning Techniques | Sakthi Jaya Sundar Rajasekar | ![]() |
![]() |
|||
PO-057 | Local Safety Standards for Invasive Procedures (LocSSIPs) in Haematology | Zeba Ahmed | ![]() |
![]() |
|||
PO-058 | Audit of uptake and user satisfaction of Attend Anywhere video consultations in Haematology outpatients QHB | Mariyam Eman Iqbal | ![]() |
![]() |
|||
PO-059 | Haematology Teams Handover: Improving Communication, Improving Patient Safety. | Iman Qureshi | ![]() |
![]() |
|||
PO-060 | Educational preferences in Maternal Haematology- A needs assessment | Sajida Kazi | ![]() |
![]() |
|||
PO-062 | Educational Videos on Haematology Practical Procedures: A UK First in Online High-Quality Open Access Resources | Angharad Everden | ![]() |
![]() |
|||
PO-063 | Assessment of Anti A and anti B IgM Titre Levels Among Aphaeresis Platelet Donors at National Blood Centre | Achana Obris | ![]() |
![]() |
|||
PO-064 | A Nurses experience of becoming a Chief Investigator and how they can benefit the wider Haematology research team | Emma Williams | ![]() |
![]() |
|||
PO-065 | Building Resilience in Face of Change Fatigue | Sarah Whitaker | ![]() |
![]() |
|||
PO-067 | Liaison haematology: starting to quantify the hidden patient need | Gillian Lowe | ![]() |
![]() |
|||
PO-068 | CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK-INHIBITOR-NAVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY | Adam Mead | ![]() |
![]() |
|||
PO-069 | Advanced systemic mastocytosis with clonal emergence of acute myeloid leukaemia while receiving the KIT D816V inhibitor avapritinib: successfully managed by allogeneic haematopoietic cell transplantation. | Priya Sriskandarajah | ![]() |
![]() |
|||
PO-070 | CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS ADD-ON TO RUXOLITINIB, IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY | Tim Somervaille | ![]() |
![]() |
|||
PO-071 | An interesting case highlighting the need to test for JAK2 fusions | Christopher Mullen | ![]() |
![]() |
|||
PO-072 | A Longitudinal Population-Level Analysis of Healthcare Resource Utilization and Morbidities in Idiopathic Multicentric Castleman Disease Patients | Martin Todd | ![]() |
![]() |
|||
PO-073 | Long-term Safety of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Treating Immune Thrombocytopenia and Rheumatoid Arthritis | Duncan Stacey | ![]() |
![]() |
|||
PO-074 | MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAKI-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS | Adam Mead | ![]() |
![]() |
|||
PO-075 | Abnormal serum protein electrophoretic pattern of patients with severe Sars-CoV-2 infection in the Intensive Care Unit reveals very high levels of dimeric form of alpha-2-macroglobulin | Mahesh Prahladan | ![]() |
![]() |
|||
PO-076 | HYPOPHOSPHATEMIA FOLLOWING FERRIC CARBOXYMALTOSE (FCM) INFUSIONS AND ITS ASSOCIATED FACTORS | Lawanya Wijesekara | ![]() |
![]() |
|||
PO-077 | A survey of healthcare professionals in the United Kingdom to describe current pathways and management practices in chronic myeloid leukaemia: the ADAPT CML survey | Onyinye Diribe | ![]() |
![]() |
|||
PO-078 | Real-World Survival Among Patients With Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval | Srdan Verstovsek | ![]() |
![]() |
|||
PO-079 | Outcomes of Haematology Patients Requiring Admission to ICU: Experience from a UK Tertiary Centre | Alexander Glover | ![]() |
![]() |
|||
PO-080 | ITP treatment-associated osteoporosis risk assessment in a Haematology cohort | Mark Ferguson | ![]() |
![]() |
|||
PO-081 | Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom (TRAPeze UK study) | Emma Geldman | ![]() |
![]() |
|||
PO-082 | Are advisory letters an acceptable alternative to in-person outpatient clinic reviews? A retrospective analysis of referrals to a haematology outpatient clinic | Fiona Lynott | ![]() |
![]() |
|||
PO-083 | Utility of urinary prostaglandin & N methyl histamine measurements across mast cell disorders (Mastocytosis, Hereditary Alpha Tryptasemia and Mast cell activation syndromes) | Bethan Myers | ![]() |
![]() |
|||
PO-085 | Management of anaemia in medical oncology patients in a day unit setting. | Katrina Fordwor | ![]() |
![]() |
|||
PO-086 | The outcome following a COVID-19 diagnosis on haematology patients; data from the South East Scotland Cancer Network | Sarah Beverstock | ![]() |
![]() |
|||
PO-087 | A review of primary care electronic advice requests to a tertiary centre Haematology department. | Eamon Mahdi | ![]() |
![]() |
|||
PO-088 | Features of the Course of Various Clinical Forms of Polycythemia Vera. | Fidan Khalilova | ![]() |
![]() |
|||
PO-089 | Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediate- or high-risk myelofibrosis previously treated with ruxolitinib | Claire Harrison | ![]() |
![]() |
|||
PO-090 | A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104) | Catrina Tice | ![]() |
![]() |
|||
PO-091 | A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103) | Catrina Tice | ![]() |
![]() |
|||
PO-092 | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib | Catrina Tice | ![]() |
![]() |
|||
PO-093 | Long-term efficacy of first-line versus second-line pegylated interferon in the treatment of essential thrombocythaemia and polycythaemia vera - results of a single-centre retrospective audit | Daniel James | ![]() |
![]() |
|||
PO-094 | PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physicians Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia | Allison Baker | ![]() |
![]() |
|||
PO-095 | Pre-operative anaemia pathway for elective orthopaedic surgery at Manchester University Foundation Trust (MFT) | Yasmin Samir | ![]() |
![]() |
|||
PO-096 | A Two-Part Phase 2 Study of Itacitinib Immediate Release in Patients with Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy | Catrina Tice | ![]() |
![]() |
|||
PO-097 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor TreatmentNave Myelofibrosis | Catrina Tice | ![]() |
![]() |
|||
PO-098 | Development of a prescribing checklist: implementing change to improve the safety and accuracy of rasburicase prescribing in chemotherapy patients | Elizabeth Brook | ![]() |
![]() |
|||
PO-099 | Impact of JAK2V617F Mutation on Coagulation Function Tests and Inflammatory Markers in Sudanese Patients with Essential Thrombocythemia | Sahar Elbaget | ![]() |
![]() |
|||
PO-100 | Experience with Pegasys in patients with Myeloproliferative Neoplasm | Jaymathi Dhanapal | ![]() |
![]() |
|||
PO-101 | Management of postpartum anaemia | Catherine Prodger | ![]() |
![]() |
|||
PO-102 | TREATMENT FREE REMISSION IN TUNISIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA | Rim Frikha | ![]() |
![]() |
|||
PO-103 | Efficacy and Safety of Pegylated Interferon in Myeloproliferative Neoplasms A Regional Experience. | Eileen Ryan | ![]() |
![]() |
|||
PO-104 | A case of polycythaemia vera treated with ropeginterferon-2b during pregnancy | Irene Sanchez | ![]() |
![]() |
|||
PO-105 | A Diagnostic Conundrum: Coombs-negative, Steroid Refractory Hemolytic Anemia with Reduced Reticulocyte Index Despite a Functioning Marrow | Scott Mayer | ![]() |
![]() |
|||
PO-106 | Dramatic constitutional deterioration following switch to generic imatinib: a case report and one centres experience | Kinda Al-Hourani | ![]() |
![]() |
|||
PO-107 | Effect of Metformin-induced Serum Vitamin B12 Deficiency on Haematological parameters in Type 2 diabetes patients. | Alozie Eze | ![]() |
![]() |
|||
PO-108 | Resolution, following treatment with rasburicase, of obstructive nephropathy caused by uric acid calculi as a presenting feature of chronic myeloid leukaemia | Tom Bull | ![]() |
![]() |
|||
PO-109 | Review of Intrapartum Management of ITP in Pregnancy in John Radcliffe Hospital | Jaymathi Dhanapal | ![]() |
![]() |
|||
PO-110 | THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA WITH TYROSINE KINASE INHIBITORS - A SINGLE CENTRE RETROSPECTIVE REVIEW | Fiona Lynott | ![]() |
![]() |
|||
PO-111 | A bone marrow diagnosis: metastatic melanoma with no primary | Sarah Beverstock | ![]() |
![]() |
|||
PO-112 | The Diagnosis, Treatment and Monitoring of Patients with Chronic Myeloid Leukaemia: The Impact of ELN Guidelines on Clinical Practice in a District General Hospital | Muttuswamy Sivakumaran | ![]() |
![]() |
|||
PO-113 | Does Obstructive Sleep Apnoea Really Cause Polycythaemia? | Sally Keat | ![]() |
![]() |
|||
PO-114 | A Rare Case of Posterior Reversible Encephalopathy Syndrome in Acute Intermittent Porphyria leading to seizures and cardiac arrest | Arina Madan | ![]() |
![]() |
|||
PO-115 | The effect of an ambulatory care pathway on management of anaemia in a district general hospital | Pooja Mahapatra | ![]() |
![]() |
|||
PO-116 | Evaluation of a new reticulated platelet parameter using an ADVIA 2120i | Graham Gibbs | ![]() |
![]() |
|||
PO-117 | Knowledge and attitude towards blood donation and prevalence of hepatitis B and C among secondary school teachers in Calabar, Nigeria | Patience Akpan | ![]() |
![]() |
|||
PO-118 | An audit of blood transfusions on an inpatient haematology unit in an English teaching hospital: what percentage of transfusions are given overnight and what factors contribute to this? | Amanda Adams | ![]() |
![]() |
|||
PO-119 | Choosing the platform for ABO antibody titration | Divya Setya | ![]() |
![]() |
|||
PO-120 | Hematological laboratory results and clinical outcome in pregnancy with SARS-COVID-19 infection, a single centre case control study | Farooq Wandroo | ![]() |
![]() |
|||
PO-121 | Impact of the SARS-Cov-2 (COVID-19) viral pandemic on Blood Transfusion laboratory activity, including pre-transfusion testing and blood component utilisation: A Single-centre Experience | Prabal Mittal | ![]() |
![]() |
|||
PO-122 | Rationalising Pre-Operative Trauma Bloods Can Lead to Significant Cost Savings | David Keohane | ![]() |
![]() |
|||
PO-123 | Knowledge, attitudes and practices surrounding voluntary non-remunerated blood donation among medical and non-medical students at The University of the West Indies in Trinidad and Tobago | kenneth charles | ![]() |
![]() |
|||
PO-124 | Single centre review of granulocyte use | Rodothea Amerikanou | ![]() |
![]() |
|||
PO-126 | RhD cell-free fetal DNA screening results in reduction of anti-D use at Guys and St Thomas Hospital | Charlene Furtado | ![]() |
![]() |
|||
PO-128 | An audit of allocation of Paedipacks to polytransfused neonates in a tertiary neonatal unit | Frederick Soole | ![]() |
![]() |
|||
PO-129 | Can haematological markers of COVID-19 positive patients at presentation to hospital predict subsequent Intensive Treatment Unit (ITU) admission and mortality? | Sami Hussain | ![]() |
![]() |
|||
PO-130 | Diagnosis and management of a patient with probable alloantibody towards the universal Kell antigen (Ku) | Susudu Jayanetti | ![]() |
![]() |
|||
PO-131 | Avoidable Out-of-Hours Red Cell Transfusions: A Retrospective Audit at a District General Hospital | Joanna Fawcett | ![]() |
![]() |
|||
PO-132 | A Low Mean Platelet Volume Indicates Active Inflammatory Bowel Disease; A Sensitive Model in Resource Poor Settings. | Hirosha Fernando | ![]() |
![]() |
|||
PO-133 | A review of granulocyte use in Scotland for the year 2020. | Dáire Quinn | ![]() |
![]() |
|||
PO-134 | Investigation of ABO-incompatible RBC transfusions in a tertiary care hospital in Tunis | Mahjoub Sonia | ![]() |
![]() |
|||
PO-135 | Red cell transfusion practices and the clinical outcome of transfusion among neonates in the Neonatal Intensive Care unit Sri Jayewardanepura General Hospital Sri Lanka. | Sachintha Abeyrathna | ![]() |
![]() |
|||
PO-136 | Determinants of voluntary blood donation among female students in a tertiary institution in Nigeria | Mutiat Ogunfemi | ![]() |
![]() |
|||
PO-137 | To improve efficiency of haematology junior doctor working by reducing ad hoc G&S sample requests-A Quality Improvement Project | Maira Hafeez | ![]() |
![]() |
|||
PO-138 | Abnormal haematological parameters in COVID 19 positive patents. A single centre study from the United Kingdom. | Mahesh Prahladan | ![]() |
![]() |
|||
PO-140 | A RETROSPECTIVE ANALYSIS OF THE ASSOCIATION OF IRON DEFICIENCY STATUS AND ITS EFFECT ON SEVERITY IN PATIENTS WITH DENGUE FEVER IN A TERTIARY CARE HOSPITAL IN SRI LANKA | Dinesh Ranasinghe | ![]() |
![]() |
|||
PO-141 | Usage of Therapeutic plasma Exchange(TPE) in leptospirosis associated severe pulmonary haemorrhagic syndrome | SANDUN MAHESHA GUNAWARDENE | ![]() |
![]() |
|||
PO-142 | Case Report: Therapeutic Plasma Exchange in Acute Liver Injury Following Paracetamol Over Dose | Pabasara Premarathne | ![]() |
![]() |
|||
PO-143 | G-6-PD Deficiency in Crete, Greece during the last five years. | Maria Maisi | ![]() |
![]() |
|||
PO-144 | Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results | Abraham Jacob | ![]() |
![]() |
|||
PO-145 | Pirtobrutinib (LOXO-305), a next generation highly ive non-covalent Brutons Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study | Toby Eyre | ![]() |
![]() |
|||
PO-146 | Long-Term Survival and Gradual Recovery of B Cells in Patients With Refractory Large B-Cell Lymphoma Treated With Axicabtagene Ciloleucel | Kayla Lane | ![]() |
![]() |
|||
PO-147 | Brentuximab vedotin with chemotherapy for previously untreated, stage III/IV classical Hodgkin lymphoma: 5 year update of the ECHELON 1 study | John Radford | ![]() |
![]() |
|||
PO-148 | Prophylactic Corticosteroid Use With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma | Kayla Lane | ![]() |
![]() |
|||
PO-149 | Retreatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5 | Kayla Lane | ![]() |
![]() |
|||
PO-150 | Transcriptional Suppression of WEE1 and PARP1 genes improve Sensitivity to Rituximab: A Novel Promising targets to overcome drug Resistance in Diffuse Large B-Cell Lymphoma | Nashwa El-Khazragy | ![]() |
![]() |
|||
PO-151 | CheckMate 436: Primary efficacy and safety analysis of the phase 2 study evaluating nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma | Graham Collins | ![]() |
![]() |
|||
PO-152 | The risks of hematological toxicities and bleeding with acalabrutinib in the treatment of chronic lymphocytic leukaemia | Thura Htut | ![]() |
![]() |
|||
PO-153 | Extrapolating progression free survival curves in chronic lymphocytic leukaemia (CLL) using peripheral blood minimal residual disease (MRD) measurements from venetoclax trials | Daniel Martins | ![]() |
![]() |
|||
PO-154 | A Phase 1 Study Of CC-92480, A Novel CELMoD Agent, In Patients With Relapsed/Refractory Multiple Myeloma: Pharmacodynamic Effects Of Dose And Schedule | Eleni Tsepa | ![]() |
![]() |
|||
PO-155 | Population-based cohort study of the efficacy of Brentuximab-Vedotin in relapsed Systemic Anaplastic Large Cell Lymphoma using Public Health England data | Sarah Halligan | ![]() |
![]() |
|||
PO-156 | Parathyroid hormone levels and prognosis in multiple myeloma? | Joanna Tung | ![]() |
![]() |
|||
PO-158 | Atypical Infections with BCRi: Real World Data in Chronic Lymphocytic Leukaemia Patients from a London Tertiary Referral Centre | Hanna Renshaw | ![]() |
![]() |
|||
PO-159 | The psychological impact of the COVID-19 pandemic on Multiple Myeloma patients | Michael Campbell | ![]() |
![]() |
|||
PO-160 | Patient preferences, treatment satisfaction and quality of life in newly diagnosed and relapsed/refractory multiple myeloma patients receiving injectable-containing or fully oral therapies: the EASEMENT study | Neil Rabin | ![]() |
![]() |
|||
PO-161 | The Promoting Individualised Self-Management and Survivorship (PrISMS) clinic - a multidisciplinary remote monitoring clinic for a patient-centred approach in multiple myeloma | Catherine Lecat | ![]() |
![]() |
|||
PO-162 | Thromboprophylaxis in patients with myeloma on imid therapies - an audit of outcomes following introduction of direct oral anticoagulants. | Fatima Jamil | ![]() |
![]() |
|||
PO-163 | Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials | James Wu | ![]() |
![]() |
|||
PO-165 | Single Centre Real World Experience of the Management of Elderly Patients with High Grade Non-Hodgkin Lymphoma Using Rituximab, Cyclophosphamide and Etoposide | Angharad Everden | ![]() |
![]() |
|||
PO-166 | Identifying a subgroup of patients with asymptomatic myeloma who have a low risk of disease progression and long duration of stable disease | Philip Cannon | ![]() |
![]() |
|||
PO-167 | Service improvement and re-design during the COVID-19 Pandemic: sharing our Myeloma clinic experience | Mai Khalifa | ![]() |
![]() |
|||
PO-168 | The first Early Access to Medicines Scheme in Relapsed and Refractory Multiple Myeloma | Sheetal Fermahan | ![]() |
![]() |
|||
PO-169 | Teenage & Young Adult Haematology Patients Have Low Antibody Levels After Standard Chemotherapy Which Respond To Post-Treatment Immunisation | Lucinda Eve Sanders | ![]() |
![]() |
|||
PO-170 | The impact of isatuximab treatment on monitoring monoclonal protein concentration in myeloma | Rachel Wheeler | ![]() |
![]() |
|||
PO-171 | Are there any variables and clinical significance in length of stay for patients with diffuse large B-cell lymphoma receiving high dose methotrexate prophylaxis for central nervous system relapse? | Maxine Rudkin | ![]() |
![]() |
|||
PO-172 | Glioblastoma, IDH-wildtype a new association with IgM paraproteinaemic neuropathy? | Dana Lewis | ![]() |
![]() |
|||
PO-173 | An Automated Pipeline to Assess Treatment Response and Treatment Eligibility in Myeloma | Thomas Coats | ![]() |
![]() |
|||
PO-174 | Fracture risk in lymphoma: no longer a bone of contention | Keir Pickard | ![]() |
![]() |
|||
PO-175 | Has COVID-19 affected the presentation of patients with lymphoid malignancies? | Sarah Beverstock | ![]() |
![]() |
|||
PO-176 | Real world outcomes of fourth line daratumumab for relapsed/refractory myeloma in two UK centres | Sophie Smith | ![]() |
![]() |
|||
PO-177 | Real world single-centre experience of daratumumab monotherapy in heavily pretreated relapsed/ refractory multiple myeloma | Irene Sanchez | ![]() |
![]() |
|||
PO-178 | Incidence of fragility fracture risk factors and management of bone related complications in people treated for Lymphoma with glucocorticoid containing regimens, a single centre experience. | charlotte bloodworth | ![]() |
![]() |
|||
PO-179 | Improved outcome in elderly patients with advanced stage Diffuse Large B-Cell Lymphoma if completion of intended 6 cycles of R-CHOP21: A single centre study of patients receiving first-line treatment for DLBCL | Annabel Hill | ![]() |
![]() |
|||
PO-180 | Case series: Transformed Follicular Lymphoma treated with Lenalidomide | Nicholas Lafferty | ![]() |
![]() |
|||
PO-181 | Bone Marrow Biopsy in the Staging of Hodgkin Lymphoma - Breaking the Habit | Michael Caruana Dingli | ![]() |
![]() |
|||
PO-182 | An Audit of 2 Week Wait Referrals to the Lymphoma Clinic at University Hospital Southampton Before and During the Coronavirus Pandemic | Nicola Campbell | ![]() |
![]() |
|||
PO-183 | DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma | Alex Medaglia | ![]() |
![]() |
|||
PO-184 | Central Nervous System Aspergillosis Complicating Ibrutinib Chemotherapy: A Case Series | Sally Keat | ![]() |
![]() |
|||
PO-185 | Experience in a Large District General Hospital of Excision versus Core Needle Lymph Node Biopsy over a Five Year Period | Chibuzo Mowete | ![]() |
![]() |
|||
PO-186 | Apixaban in the prevention of thromboembolism in patients with Multiple Myeloma receiving immunomodulatory medications. Real world experience - data from two centers in North Wales, United Kingdom | Aswathi Balakrishnan | ![]() |
![]() |
|||
PO-187 | Microsatellite aberrations dynamics in relapse and progression of follicular lymphoma | Kseniia Sychevskaya | ![]() |
![]() |
|||
PO-188 | Infectious complications related to the treatment of Chronic Lymphocytic Leukaemia: Comparison of risks associated with chemoimmunotherapy and ibrutinib | Katriona Hutchison | ![]() |
![]() |
|||
PO-189 | DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone vs Pomalidomide plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma | Alex Medaglia | ![]() |
![]() |
|||
PO-190 | Impact of comorbidity on therapeutic intent and treatment outcomes in older adult patients with diffuse large B-cell lymphoma | Karen Valdés Díaz | ![]() |
![]() |
|||
PO-191 | BISPHOSPHONATE USE IN MULTIPLE MYELOMA: AN AUDIT OF COMPLIANCE AND COST ANALYSIS | Daniel Farrugia | ![]() |
![]() |
|||
PO-192 | The Management of Lymphoma and Chronic Lymphocytic Leukaemia Patients On Long Term Intravenous Immunoglobulin Replacement Therapy: A Single Centre Experience. | Nagah Elmusharaf | ![]() |
![]() |
|||
PO-193 | A retrospective single-centre cohort study of the efficacy and safety of daratumumab with bortezomib and dexamethasone therapy for previously treated multiple myeloma | Irene Sanchez | ![]() |
![]() |
|||
PO-194 | Long-term survival outcomes in Multiple Myeloma: A single centre experience | Zong Xuan Lee | ![]() |
![]() |
|||
PO-195 | The significance of lymphocytosis in routine clinical practice: data from the South East Scotland Cancer Network | Gabrielle Clark | ![]() |
![]() |
|||
PO-196 | A Different Person Entirely: Adolescent and Young Adults Experiences Returning to Education after Treatment for Haematological Malignancies | Cameron Magrath | ![]() |
![]() |
|||
PO-197 | How does survival differ by treatment route in elderly DLBCL? | Catherine Turner | ![]() |
![]() |
|||
PO-198 | Multicentre analysis on the outcome and incidence of invasive cerebral aspergillosis in haemato-oncology patients following ibrutinib treatment | Mahesh Prahladan | ![]() |
![]() |
|||
PO-199 | Audit and case series of Primary CNS lymphoma at a single centre between 2010 and 2020 excluding those treated with MATRIX chemotherapy or Autologous Stem Cell Transplant. | Patrick Sarkies | ![]() |
![]() |
|||
PO-200 | Immunoglobulin replacement therapy - The unexpected advantages of a Pandemic in one Haematology Unit | Ramya Ramya | ![]() |
![]() |
|||
PO-201 | Immunotactoid Glomerulonephritis in a donor kidney | Chinonye Onyeocha | ![]() |
![]() |
|||
PO-203 | Management of patients with Diffuse Large B cell Lymphoma not fit for anthracycline based chemotherapy at North Wales Cancer Center: | Durgadevi Moratuwagama | ![]() |
![]() |
|||
PO-204 | A Single Centre Study to Assess Awareness Among Health Care Professionals of Vaccination Advice in Chronic Lymphocytic Leukaemia | Grace Cox | ![]() |
![]() |
|||
PO-205 | C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials | Raymond Wong | ![]() |
![]() |
|||
PO-206 | The Effect Of Luspatercept On Erythropoiesis Biomarkers In MEDALIST Trial Patients With Lower-Risk Myelodysplastic Syndromes | James Matthews | ![]() |
![]() |
|||
PO-207 | Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial | Régis Peffault de Latour | ![]() |
![]() |
|||
PO-208 | Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Previously Treated with Eculizumab: A Matching-Adjusted Indirect Comparison | Rachel Bhak | ![]() |
![]() |
|||
PO-209 | Effects of Luspatercept on Health-Related Quality Of Life Outcomes For Patients With Transfusion-Dependent Beta-Thalassaemia In The BELIEVE Trial | Jacqueline Moy | ![]() |
![]() |
|||
PO-210 | Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry | Colin Griffim | ![]() |
![]() |
|||
PO-211 | High sensitivity PNH Clone testing in Patients with hematological disorders | Zohra Farooq | ![]() |
![]() |
|||
PO-212 | Improvements in Fatigue and Physical Function Evaluated Through Changes in Clinical Outcomes in Paroxysmal Nocturnal Hemoglobinuria: Post-Hoc Analyses from the PEGASUS Study | David Cella | ![]() |
![]() |
|||
PO-213 | Discharge opioid prescribing in patients with sickle cell anaemia after an admission for a sickle cell crisis | Constantina Pitsillides | ![]() |
![]() |
|||
PO-214 | Serum ferritin is under requested in the 1 to 5 age group: Relationship between mean corpuscular volume and serum ferritin | Grainne Okeeffe | ![]() |
![]() |
|||
PO-215 | Efficacy and safety of ravulizumab in older patients aged 65 years with paroxysmal nocturnal hemoglobinuria in the 301 and 302 phase 3 extension studies | Colin Griffin | ![]() |
![]() |
|||
PO-216 | The Unique Therapeutic Mechanisms in a Sickle Cell Pain Management Programme | Ji Yeon Park | ![]() |
![]() |
|||
PO-217 | Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab | Alexander Rth | ![]() |
![]() |
|||
PO-218 | Injection-Site Reactions in the Randomized Phase 3 PEGASUS Trial of Pegcetacoplan Compared with Eculizumab for Individuals with Paroxysmal Nocturnal Hemoglobinuria | Vivek Sharma | ![]() |
![]() |
|||
PO-219 | Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks | Colin Griffin | ![]() |
![]() |
|||
PO-220 | Incomplete Complement Inhibition In Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) On Eculizumab - 5 Year Experience From The National PNH Service Leeds | Rachael Jones | ![]() |
![]() |
|||
PO-221 | The use of hydroxycarbamide in sickle cell patients across the South Thames Sickle and Thalassaemia Network | Kathryn McVinnie | ![]() |
![]() |
|||
PO-222 | Methaemoglobinemia and G6PD in a patient for major surgery: Diagnostic dilemma & therapeutic enigma | Arun V J | ![]() |
![]() |
|||
PO-223 | Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria with or without a history of bone marrow disorder receiving ravulizumab and eculizumab: results from a phase 3 non-inferiority study extension | Colin Griffin | ![]() |
![]() |
|||
PO-224 | A delayed diagnosis of Blue rubber bleb nevus syndrome: characterized by refractory iron deficient anemia | Qiaoli Li | ![]() |
![]() |
|||
PO-225 | EPIDEMIOLOGICAL CHARACTERS OF ADULT EGYPTIAN SICKLE CELL ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE | Mohamed Elbogdady | ![]() |
![]() |
|||
PO-226 | EPIDEMIOLOGICAL CHARACTERS OF ADULT EGYPTIAN Auto Immune Heamolytic ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE | Mohamed Elbogdady | ![]() |
![]() |
|||
PO-227 | Thalassemia awareness among Iraqi people in 2018 | Hashim Talib Hashim | ![]() |
![]() |
|||
PO-228 | Implications of the Covid-19 Pandemic for Patients on Long-term Anticoagulants: A DOAC Switching Program in a Teaching Hospital Based Anticoagulant Service | Lishel Horn | ![]() |
![]() |
|||
PO-229 | Chronic oral anti coagulation and COVID-19; Does it make any difference? | Ammar Ashfaq | ![]() |
![]() |
|||
PO-230 | Reversal of anticoagulation with PCC every minute counts | Jennifer Davies | ![]() |
![]() |
|||
PO-231 | Use of the HemosIL Acustar ADAMTS13 functional assay as the basis for Bethesda style inhibitor detection in acquired Thrombotic Thrombocytopaenic Purpura | Ana Vaz | ![]() |
![]() |
|||
PO-232 | Management of Spontaneous Intra-Cranial Haemorrhage whilst on a Direct Oral Anticoagulant is less well known than Warfarin | Elizabeth Ryan | ![]() |
![]() |
|||
PO-233 | Major non elective orthopaedic surgery on a severe haemophilia A patient on emicizumab (without inhibitors): a case study | Udaya Reddy | ![]() |
![]() |
|||
PO-234 | For women with a previous venous thromboembolism, is standard dose thromboprophylaxis adequate in pregnancy? | Bethan Myers | ![]() |
![]() |
|||
PO-235 | Virtual clinics The Future of Thrombosis and Anticoagulant Consultations? A patient Preference Survey. | Nicole Makariou | ![]() |
![]() |
|||
PO-236 | Thromboprophylaxis and the D-Dimer in critically unwell patients with Covid-19. A UK single centre experience. | Olga Tsiamita | ![]() |
![]() |
|||
PO-237 | ADAMTS13 activity trends in TTP patients with COVID-19 infection | Rebecca Jane Shaw | ![]() |
![]() |
|||
PO-238 | Optimising COVID-19 thromboprophylaxis within the critical care unit of a large UK-based teaching hospital | Louis Gardner | ![]() |
![]() |
|||
PO-239 | Perioperative management of anticoagulation: an audit of complications | Paul Armitage | ![]() |
![]() |
|||
PO-240 | Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies | Michael Desborough | ![]() |
![]() |
|||
PO-241 | Assessing the utility of the pregnancy-adapted YEARS algorithm in predicting presence of PE in pregnant women with suspected PE. | Bethan Myers | ![]() |
![]() |
|||
PO-242 | Covid 19 and practice in the Haemostasis Lab findings from a UK NEQAS (blood Coagulation) questionnaire. | Ian Jennings | ![]() |
![]() |
|||
PO-243 | Reduction in Hospital Associated Thrombosis at Hampshire Hospitals (HHFT) due to innovative cross specialty collaboration during COVID-19 pandemic. | Tracy May | ![]() |
![]() |
|||
PO-244 | Changes to coagulation factors in critically ill patients with SARS-CoV-2 infection | Styliani Salta | ![]() |
![]() |
|||
PO-245 | Thrombotic complications among hospitalized Covid-19 patients in a tertiary care hospital in Karachi, Pakistan | Taymmia Ejaz | ![]() |
![]() |
|||
PO-246 | An Audit of Warfarin to Direct Oral Anticoagulant (DOAC) Switches: Implications for the COVID-19 Era and Beyond | Jayasekara Prasangika | ![]() |
![]() |
|||
PO-247 | Predictors for prognosis in patients with nonfatal Pulmonary Embolism in COVID19 pandemic | Nadejda Diaconu | ![]() |
![]() |
|||
PO-248 | A multi-professional approach to improving awareness of cancer-associated thrombosis amongst people with cancer at the Northern Centre for Cancer Care in the United Kingdom | Iona Cutforth | ![]() |
![]() |
|||
PO-249 | Prevalence of cardiovascular disease and risk factors among adult patients with haemophilia, an experience in a tertiary care hospital clinic in Sri Lanka. | Thamudika Vithanage | ![]() |
![]() |
|||
PO-250 | Evaluation of plasma fibrinogen level in patients who have undergone extracorporeal circulation | Mahjoub Sonia | ![]() |
![]() |
|||
PO-251 | A Rare Presentation of ST-segment Elevation Myocardial Infarction Associated with Ovarian Stimulation in the Absence of Ovarian Hyperstimulation Syndrome | Keun Young Kim | ![]() |
![]() |
|||
PO-252 | Management appropriateness and outcomes of patients with acute pulmonary embolism in COVID-19 pandemic | Nadejda Diaconu | ![]() |
![]() |
|||
PO-253 | Venous thromboembolism awareness among medical students in south -eastern Nigeria. A multicenter survey | Helen Okoye | ![]() |
![]() |
|||
PO-254 | Review of Utility of Royal College of Obstetricians and Gynaecologists (RCOG) guidelines in predicting pregnancy-related VTE (PA-VTE) | Bethan Myers | ![]() |
![]() |
|||
PO-255 | Hyperfibrinogenemia in patients with aggressive non-Hodgkins lymphoma | Buruiana Sanda | ![]() |
![]() |
|||
PO-256 | Acquired Thrombotic Thrombocytopenic Purpura - Single Centre Experience | Fatima AlKindi | ![]() |
![]() |
|||
PO-257 | Diagnostic uncertainty in a case of thrombotic microangiopathy | Clare Brown | ![]() |
![]() |
|||
PO-258 | Heparin-induced thrombocytopenia: a cautionary tale | Clare Brown | ![]() |
![]() |
|||
PO-259 | Lower Limb Oedema in Beckwith-Wiedemann Syndrome | Mihai-Ionut Firescu | ![]() |
![]() |
|||
PO-260 | Assessment of Vitamin K Level in Newborns Presenting with Bleeding in Population of Rural Sindh, Pakistan | Nazia Memon | ![]() |
![]() |
|||
PO-261 | A rare case of Acquired Factor 8 inhibitor in a patient with Autoimmune Hemolytic Anemia successfully treated with steroids and rituximab | Pramuditha Rajapakse | ![]() |
![]() |
|||
PO-262 | A Rare Case of Bi-atrial Thrombi in a Stage IV Pancreatic Cancer Patient with Atrial Fibrillation on Warfarin | Na Hyun Kim | ![]() |
![]() |
|||
PO-263 | A rare cause of diffuse peripheral and central thromboses | Saad Ahmed | ![]() |
![]() |
|||
PO-264 | Research of influence of virus inactivating agent on the activity of Thombin | Nataliia Shurko | ![]() |
![]() |
|||
PO-265 | Prothrombin Time, Activated Partial Thromboplastin Time and Platelets Indices of Mortuary Workers Exposed to Formaldehyde, a Base Line Study in Calabar, Nigeria | Ifeyinwa Okafor | ![]() |
![]() |
|||
PO-266 | LONG TERM OUTCOME OF BETA THALASSEMIA MAJOR PATIENTS POST ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANT-A SINGLE CENTER STUDY FROM PAKISTAN | Nabila Rafique | ![]() |
![]() |
|||
PO-267 | Outcomes of allogeneic transplantation with non-myeloablative conditioning in patients with myelodysplastic and overlap syndromes | Ammar Hilali | ![]() |
![]() |
|||
PO-268 | Bortezomib for refractory haemolytic anaemia post allogenic haematopoietic stem cell transplantation | Sophie Ganjavian | ![]() |
![]() |
|||
PO-269 | Incidence of veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation and the associated burden of disease in England: a retrospective analysis of Hospital Episode Statistics data (2010-2020) | Diane Lockard | ![]() |
![]() |
|||
PO-270 | Outcomes of patients with acute Graft versus Host Disease managed with extra-corporeal photopheresis: a single centre service evaluation following initial commissioning by NHS England | Julia Wolf | ![]() |
![]() |
|||
PO-271 | Variations in psychological care in UK stem cell transplant centres: results of a national survey | Rosalina Naidoo | ![]() |
![]() |
|||
PO-272 | Cessation of ciprofloxacin prophylaxis in haemato-oncology patients at a London teaching hospital | Louise Caldwell | ![]() |
![]() |
|||
PO-273 | Ruxolitinib for management of Graft versus host disease: Real world experience from a developing country | Muhammad Yousaf | ![]() |
![]() |
|||
PO-275 | Influence of ABO and D antigen discrepancies in allogeneic stem cell transplant : A single center study from Bangladesh | Tamanna Afroz | ![]() |
![]() |
|||
PO-999 | Prueba | Daniel Zaldumbide | ![]() |
![]() |
25-28 April 2021 Virtual Conference
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|